- Home
- PKE vs ZBIO Comparison
PKE vs ZBIO Comparison
Compare PKE & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ZBIO
- Stock Information
- Founded
- PKE 1954
- ZBIO 2019
- Country
- PKE United States
- ZBIO United States
- Employees
- PKE N/A
- ZBIO N/A
- Industry
- PKE Military/Government/Technical
- ZBIO
- Sector
- PKE Industrials
- ZBIO
- Exchange
- PKE Nasdaq
- ZBIO NYSE
- Market Cap
- PKE 260.2M
- ZBIO 389.2M
- IPO Year
- PKE N/A
- ZBIO 2024
- Fundamental
- Price
- PKE $15.31
- ZBIO $10.41
- Analyst Decision
- PKE
- ZBIO Strong Buy
- Analyst Count
- PKE 0
- ZBIO 7
- Target Price
- PKE N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- PKE 65.4K
- ZBIO 221.4K
- Earning Date
- PKE 07-15-2025
- ZBIO 08-16-2025
- Dividend Yield
- PKE 3.28%
- ZBIO N/A
- EPS Growth
- PKE N/A
- ZBIO N/A
- EPS
- PKE 0.29
- ZBIO N/A
- Revenue
- PKE $62,026,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- PKE N/A
- ZBIO $206.00
- Revenue Next Year
- PKE N/A
- ZBIO $41.92
- P/E Ratio
- PKE $51.76
- ZBIO N/A
- Revenue Growth
- PKE 10.75
- ZBIO N/A
- 52 Week Low
- PKE $11.96
- ZBIO $5.83
- 52 Week High
- PKE $15.57
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- PKE 67.47
- ZBIO N/A
- Support Level
- PKE $14.96
- ZBIO N/A
- Resistance Level
- PKE $15.41
- ZBIO N/A
- Average True Range (ATR)
- PKE 0.37
- ZBIO 0.00
- MACD
- PKE 0.12
- ZBIO 0.00
- Stochastic Oscillator
- PKE 90.82
- ZBIO 0.00
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.